Ask AI
ProCE Banner Activity

Individualizing Therapeutic Decision-Making for Patients With HR+/HER2- EBC: Downloadable Slides

Slideset

Download this slideset to review the latest data on treatment for patients with HR+/HER2- early breast cancer.

Released: May 12, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group
Barcelona, Spain
IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana
Madrid, Spain

Javier Cortes, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bioasis, Biocon, BioInvent, BioNTech, Bliss, Boehringer Ingelheim, BridgeBio, Circle, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, Expres2ion, GEMoab, Gilead, Hexagon, Hibercell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Reveal Genomics, Roche, Scorpion, Seattle Genetics, Zymeworks; honoraria: Astrazeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher: Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant, Iqvia, Merck Sharp & Dohme, Pfizer, Piqur, Roche; individual publicly traded stocks and stock options: Leuko; travel/accommodation/expense: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; royalties or patent beneficiary: Pharmaceutical Combinations of a PI3K Inhibitor and a Microtubule Destabilizing Agent (issued); HER2 as a Predictor of Response to Dual HER2 Blockade (licensed).